A clinical to evaluate the use of lenacapavir as PrEP in cisgender men, persons of trans experience and gender non-binary individuals who have sex with men
Latest Information Update: 16 Mar 2021
At a glance
- Drugs Lenacapavir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 16 Mar 2021 New trial record
- 09 Mar 2021 According to a Gilead Sciences media release, the company expects to initiate this study in 2021.